Welcome to our dedicated page for Varex Imaging SEC filings (Ticker: VREX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Varex Imaging’s dual Medical and Industrial disclosures can feel like testing an x-ray tube under maximum load—dense specs, segment swaps, and regulatory cross-checks everywhere. That’s why this page doesn’t just list documents; it decodes them. Stock Titan’s AI digs into each filing so you can see, in plain English, where detector R&D is headed, how replacement-tube revenue trends, and when security-screening orders shift the Industrial backlog.
Need the Varex Imaging quarterly earnings report 10-Q filing or last quarter’s segment margins? One click delivers the PDF plus an AI summary of revenue drivers and cash-flow swings. Tracking executive incentives? Our dashboard flags Varex Imaging insider trading Form 4 transactions and streams Varex Imaging Form 4 insider transactions real-time, giving you context on board-level confidence. When a sudden contract win hits, the Varex Imaging 8-K material events explained card highlights what changed and why it matters.
Here’s how professionals use the page:
- Compare quarterly detector sales using Varex Imaging earnings report filing analysis.
- Spot option grants via Varex Imaging executive stock transactions Form 4.
- Review R&D spend in the Varex Imaging annual report 10-K simplified section.
- Examine leadership pay through the Varex Imaging proxy statement executive compensation viewer.
- Save hours by understanding Varex Imaging SEC documents with AI instead of manual searches.
All forms—10-K, 10-Q, 8-K, S-8, DEF 14A—arrive seconds after EDGAR posts, and our AI-powered summaries keep technical jargon from clouding critical insight. In short, this is Varex Imaging SEC filings explained simply, updated in real time and ready for decisive analysis.
Pzena Investment Management LLC has filed Amendment No. 1 to Schedule 13G disclosing a passive ownership position in Varex Imaging Corporation (VREX).
- The value-oriented investment adviser now beneficially owns 4,244,977 common shares, representing 10.2 % of VREX’s outstanding stock.
- Sole voting power: 3,108,798 shares; sole dispositive power: the full 4,244,977 shares. No shares are held with shared voting or dispositive authority.
- The filing is made under Rule 13d-1(b) as an institutional investment adviser (IA), indicating the stake is held in the ordinary course of business and not for the purpose of influencing control.
- All shares are held on behalf of clients; no single client owns more than 5 % of the class.
- The filing date of the event is 30 June 2025; signature is dated 3 July 2025 by Chief Legal Risk & Compliance Officer Steven Coffey.
The >10 % threshold places Pzena among the largest institutional holders of VREX, potentially increasing trading liquidity and indicating external confidence in the company’s valuation, although the passive 13G designation suggests no activist intent.
Director Jay K. Kunkel of Varex Imaging Corp (VREX) reported a significant insider transaction on June 18, 2025. The filing discloses that Kunkel sold 2,575 shares of common stock at a price of $7.77 per share, resulting in a total transaction value of approximately $20,007.
Following this disposition, Kunkel's direct ownership position decreased to 22,477 shares of Varex Imaging common stock. The transaction was executed as a straight sale (Transaction Code: S) and was reported within the required filing deadline.
Key transaction details:
- Transaction Type: Direct sale of common stock
- Shares Sold: 2,575 at $7.77 each
- Remaining Direct Holdings: 22,477 shares
- Filing Status: Form 4 filed timely on June 20, 2025